source
- Definium says its LSD drug notched another Phase 3 win in anxiety disorderDefinium Therapeutics reported results Monday for its third Phase 3 readout this year on its oral LSD candidate, called DT120, and is gearing up for an FDA submission. The company’s late-stage data…Endpoints · 35m ago↗ source
- Akeso and Summit report survival advantage for PD-1xVEGF combo over KeytrudaAt the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific anti…